Tango Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
TNGX$24.30+6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Collaboration revenue | $5,392 | $6,471 |
| Operating expenses: | ||
| Research and development | 36,442 | 38,065 |
| General and administrative | 11,480 | 10,661 |
| Total operating expenses | 47,922 | 48,726 |
| Loss from operations | (42,530) | (42,255) |
| Other income: | ||
| Interest income | 1,614 | 2,197 |
| Other income, net | 1,074 | 2,184 |
| Total other income, net | 2,688 | 4,381 |
| Loss before income taxes | (39,842) | (37,874) |
| Provision for income taxes | (34) | (40) |
| Net loss | $(39,876) | $(37,914) |
| Net loss per common share – basic and diluted | $(0.36) | $(0.35) |
| Weighted average number of common shares outstanding – basic and diluted | 110,301,256 | 108,171,463 |
| Net loss | $(39,876) | $(37,914) |
| Other comprehensive income (loss): | ||
| Unrealized loss on marketable securities | (142) | (443) |
| Comprehensive loss | $(40,018) | $(38,357) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.